A product image of the existing AncestryHealth offering.
August 24, 2020
Consumer genomics company Ancestry recently received two FDA 510(k)s – one for an in vitro molecular test that detects genomic variants tied to potential disease risk, and another for a saliva-based DNA specimen-collection kit.
Both of these submissions were received by the FDA in October of last year, which officially cleared them on August 13, according to the agency's 510(k) database.
August 18, 2020
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need for confirmatory testing.
This action updates a De Novo approval granted to the consumer genomics company in late 2018. That decision allowed 23andMe to market a test for one of 33...
August 3, 2020
Consumer genomic company Ancestry, which got its start in providing testing for family history, is launching a new product which features next-generation sequencing. The new product aims to help customers gain insights into their health and risk factors.
Called “AncestryHealth powered by Next Generation Sequencing,” the tool can screen for genes associated with breast cancer, heart disease,...
May 13, 2020
This morning, direct-to-consumer genomics startup The DNA Company announced its purchase of digital therapeutic My Pain Sensei for roughly $30 million.
The technology from the two companies will be combined to form a new platform called My Next Health, which will use genomic information to help users get insights into preventing and managing chronic conditions.
The DNA Company notes that the...
February 18, 2020
The last month has been tough going for the consumer genomics industry with frontrunners 23andMe and Ancestory.com both announcing massive layoffs. However, new kid on the block Nebula Genomics is launching a consumer product today that will offer users whole genome sequencing for $299.
“We hope to really revitalize the whole space by making whole genome sequencing affordable, providing more...
January 23, 2020
23andMe has laid off 100 employees across its consumer business, the genomics company confirmed to MobiHealthNews.
This news come amidst disappointing sales numbers, according to CNBC, which first reported the story. In an interview with CNBC’s Chrissy Farr, 23andMe CEO Anne Wojcicki discussed potential factors contributing to what she sees as a market cooldown, top of the list being customers...
October 15, 2019
Ancestry, a consumer genomic testing company focused on family history, is now turning to the health space with its launch of AncestryHealth. The new product is aimed at giving customers insights into the health risks associated with their genes and family history.
As part of the new services customers can get tests that are ordered by doctors. The service will also provide education resources...
June 13, 2019
Genome Medical — a company that offers patient-facing virtual visits and provider-facing consultations with genetic experts — has raised $23 million in Series B funding. The round brings Genome Medical to $46 million in total funding.
The round was led by Echo Health Ventures, with participation from LRVHealth, Casdin Capital, Perceptive Advisors, Manatt Venture Fund and Dreamers Fund, as well as...
May 20, 2019
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe.
MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
March 27, 2019
Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on particular genes, as opposed to medical sequencing that is much more thorough. And, according to a 2018 study by Ambry Genetics in Genetics in Medicine, these results can be wrong — the study showed...